Glaxo Wellcome Relenza
"Dear Healthcare Professional" letter sent July 10 to highlight addition of bolded warning to zanamivir labeling. The warning addresses events of bronchospasm and decline in lung function reported in some patients, and advises against Relenza administration to patients with underlying airway disease such as asthma or chronic obstructive pulmonary disease (1"The Pink Sheet" Jan. 31, p. 20). A new patient information leaflet has been developed, and a second "Dear Healthcare Professional" letter will be mailed at the beginning of the flu season in the fall
You may also be interested in...
Glaxo Wellcome is warning European prescribers about potential side effects with Relenza one week after similar concerns were raised by FDA.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials